Data as of Sep 19
| +0.02 / +0.75%|
The 6 analysts offering 12-month price forecasts for CTi Biopharma Corp have a median target of 5.25, with a high estimate of 6.50 and a low estimate of 4.00. The median estimate represents a +95.90% increase from the last price of 2.68.
The current consensus among 6 polled investment analysts is to Buy stock in CTi Biopharma Corp. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.